• Skip to main content

DistilGovHealth

DistilNFO GovHealth Advisory

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

CMS’ final prescription drug rule: 6 things to know

Share:

May 29, 2019

CMS issued a final rule May 16 that makes several changes to Medicare Advantage and Part D. The final rule is a scaled-back version of the proposed rule.

Six things to know:

1. CMS declined to implement a proposed measure that would give insurers more flexibility around the coverage of “protected classes” of drugs. Current policy requires Medicare Part D plans to cover drugs in the following six categories: antidepressants, antipsychotics, anticonvulsants, immunosuppressants for treatment of transplant rejection, antiretrovirals, and antineoplastics. The proposed rule wanted to create exemptions to this “protected class” policy. CMS declined to allow plan sponsors to exclude a protected class drug from its formulary if it exceeded a certain price threshold or it was a new formulation of an existing single source drug.

2. However, under the final rule, Part D plans have greater leeway to implement step therapy and use prior authorization, even within the protected classes. The only class that is not able to use step therapy is antiretroviral drugs.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

3. The rule also finalized regulations for how Medicare Advantage plan can apply step therapy to physician-administered drugs under Part B. The policy will only cover the first time a patient tries a medication and it can be reviewed.

4. The rule also formally implements a ban on pharmacy “gag clauses,” where pharmacists are prohibited from informing consumers that they could save money by paying out-of-pocket instead of through their health plan. A law was signed by President Donald Trump earlier this year that makes the practice illegal.

5. CMS also declined to implement a plan that would have passed price concessions negotiated by pharmacies onto patients.

6. Under the finalized rule, Part D plans must build a tool that can be integrated into provider EHRs or E-prescribing systems to help equip clinicians with more data on drug pricing. Plan sponsors will have until Jan. 1, 2021, to launch a tool that’s compatible with at least one provider system.

Date: May 29, 2019

Source: Beckers Hospital Review

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Major Payers Find HHS Finalized Nondiscrimination Rule Too NarrowMajor Payers Find HHS Finalized Nondiscrimination Rule Too Narrow
  • New Clinically Validated Sleepcheck App LaunchesNew Clinically Validated Sleepcheck App Launches
  • Apple Still has a Lot of Room to Grow in the $3.5 Trillion Health Care SectorApple Still has a Lot of Room to Grow in the $3.5 Trillion Health Care Sector
  • Google Moves Further Into Healthcare: a Timeline of the Last YearGoogle Moves Further Into Healthcare: a Timeline of the Last Year
  • Superb Healthcare At Ultra-Low Prices? How Singapore Does ItSuperb Healthcare At Ultra-Low Prices? How Singapore Does It
  • AI, Machine Learning, and Blockchain are Key for Healthcare InnovationAI, Machine Learning, and Blockchain are Key for Healthcare Innovation

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications